Covagen develops bispecific FynomAbs by fusing its human Fynomer® binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy. Our current pipeline is focussed on the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy.
Covagen is developing COVA322 for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. COVA322 is a bispecific FynomAb® inhibiting TNF and IL-17A.